Sanquin   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Amsterdam Netherlands (1998)

Organization Overview

First Clinical Trial
2001
NCT00138697
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Sanquin | Sanquin Blood Bank North East Region | Sanquin Plasma Products BV | Sanquin Research & Blood Bank Divisions

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Agammaglobulinemia (Phase 3)

Angioedema (Phase 3)

Angioedemas, Hereditary (Phase 2)

Asthma (Phase 4)

beta-Thalassemia (Phase 2)

Cardiomyopathies (Phase 3)

Endotoxemia (Phase 3)

Erythroblastosis, Fetal (Phase 3)

Hemophilia A (Phase 4)

Hemophilia B (Phase 4)

Hereditary Angioedema Types I and II (Phase 2)

Hidradenitis (Phase 4)

Hidradenitis Suppurativa (Phase 4)

Hip Fractures (Phase 3)

HIV Infections (Phase 4)

IgG Deficiency (Phase 4)

Immunologic Deficiency Syndromes (Phase 3)

Infections (Phase 4)

Inflammation (Phase 3)

Metal Metabolism, Inborn Errors (Phase 3)

Multiple Organ Failure (Phase 3)

Multiple Sclerosis (Phase 4)

Neutropenia (Phase 2)

Osteoarthritis (Phase 4)

Parvoviridae Infections (Phase 3)

Purpura (Phase 3)

Purpura, Thrombocytopenic (Phase 3)

Purpura, Thrombocytopenic, Idiopathic (Phase 3)

Sclerosis (Phase 4)

Thalassemia (Phase 2)

Wounds and Injuries (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 27
  • # of Trial APIs: 21